

Original Research Article

Time-Dependent Variation in Immunoparalysis Biomarkers Among Patients with Sepsis and Critical Illness

Abigail Samuelson¹, Erik Lehman², Parker Burrows¹, Anthony S Bonavia^{3,*}

¹ Department of Anesthesiology and Perioperative Medicine, Penn State Hershey Medical Center, Hershey, PA 17033; asamuelsen19@gmail.com and pburrows@pennstatehealth.psu.edu

² Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA 17033; elehman@pennstatehealth.psu.edu

³ Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, Penn State Hershey Medical Center, Hershey, PA 17033; abonavia@pennstatehealth.psu.edu

* Correspondence: abonavia@pennstatehealth.psu.edu

Abstract: Immunoparalysis is a significant concern in patients with sepsis and critical illness, potentially leading to increased risk of secondary infections. This study aimed to perform a longitudinal assessment of immune function over the initial two weeks following the onset of sepsis and critical illness. We compared ex vivo stimulated cytokine release to traditional markers of immunoparalysis, including monocyte Human Leukocyte Antigen (mHLA)-DR expression and absolute lymphocyte count (ALC). A total of 64 critically ill patients were recruited in a tertiary care academic medical setting, including 31 septic and 33 non-septic patients. Results showed that while mHLA-DR expression significantly increased over time, this was primarily driven by the non-septic subset of critically ill patients. ALC recovery was more prominent in septic patients. Ex vivo stimulation revealed significant increases in TNF and IL-6 production over time in septic patients. However, IFN γ production varied with the stimulant used and did not show significant recovery when normalized to cell count. No significant correlation was found between mHLA-DR expression and other immunoparalysis biomarkers. These findings suggest the need for more nuanced immune monitoring approaches beyond the traditional 'sepsis' versus 'non-sepsis' classifications in critically ill patients. It also provided further evidence of a potential window for targeted immunotherapeutic interventions in the first week of critical illness.

Keywords: sepsis, critical illness, immune monitoring, immunodeficiency, Human Leukocyte Antigen-DR, lymphocyte count

1. Introduction

Sepsis, marked by host immune dysregulation and subsequent organ dysfunction, is a leading cause of critical illness, often resulting in death within days to months after the onset of acute illness [1]. Patient mortality rates in the intensive care unit have been cited as high as 30% [2-5]. Furthermore, secondary infection, resulting from sepsis-induced impairment of host immunity, is a well-recognized cause of morbidity [6]. One study found 69% of hospital readmissions were related to infection, with over 50% of those as recurrent or unresolved infections [7]. This 'immunoparalysis' is multifactorial [8,9], driven by immune cell exhaustion and apoptosis [10-12], anti-inflammatory cytokine production [13-16], metabolic dysfunction [17,18], and the expansion of regulatory T cells [19-22] and myeloid-derived suppressor cells [23,24].

Significant efforts have been made to identify immune phenotypes in sepsis to develop clinically useful risk-stratification tools that could improve clinical outcomes. A recent, landmark study by Venet and the REALISM (REAnimation Low Immune Status Marker) investigators identified a subgroup of severely injured patients who developed delayed injury-acquired immunodeficiency, independent of the primary disease [25]. These findings suggest that immunoparalysis is not specific to sepsis but can be assessed in critically ill patients by monitoring a common panel of complementary markers of pro-/anti-inflammatory, innate, and adaptive immune responses. Moreover, this research highlights the urgent need to identify routinely accessible immunosurveillance markers to pinpoint patients who might benefit from customized immunoadjuvant therapies [26]. Given the rapid progression of sepsis and the narrow window for effective clinical intervention, it is also important that these biomarkers can be rapidly processed in a point-of-care clinical setting.

Based in part on these insights, our lab has pioneered a fast and precise assay for detecting immunoparalysis. We recently reported that ex vivo stimulation of both innate and adaptive immune system components did not predict

secondary infection rates but reliably predicted organ function within 48 hours of the assay [27]. Clustering analysis further revealed two distinct immune phenotypes, characterized by differential responses to 18 hours of lipopolysaccharide (LPS, or endotoxin) and 4 hours of anti-CD3/anti-CD28 stimulation.

The present analysis aimed to use these assays to survey immune function over the first two weeks following the onset of sepsis and critical illness. Specifically, our goal was to compare *ex vivo*, stimulated cytokine release to traditional markers of immunoparalysis, including monocyte Human Leukocyte Antigen (mHLA)-DR expression (a biomarker of innate immunity) and absolute lymphocyte count (ALC, a biomarker of adaptive immunity) [28]. We hypothesized that patterns in *ex vivo*, stimulated cytokine responses over time would mirror those of mHLA-DR expression and ALC. Due to challenges in reliably identifying secondary infections, including inconsistent diagnostic criteria and underreporting [29-31], we defined immunoparalysis based on immune parameters alone.

2. Results

2.1 Study Population

Demographic and Clinical Characteristics	Critically Ill, Septic (n = 31)	Critically Ill, Non-Septic (n = 33)	P-value
Age (mean ± SD)	65.5 ± 13.4	64.1 ± 15.4	0.708
Female (n, %)	14 (48)	15 (52)	0.981
Infection etiology (n, %)			
---Gram-negative	11	N/A	
---Gram-positive	9	N/A	
---Mixed	11	N/A	
---Clinical diagnosis only, no positive cultures	2	N/A	
Severity of illness			
APACHE II Score (mean ± SD)	21.1 ± 7.1	18.4 ± 6.7	0.123
SOFA Score (median, IQR)	8.0 (7.1, 9.7)	6.0 (5.7, 7.9)	0.042
Charlson Comorbidity Index (median, IQR)	5.0 (4.0, 5.9)	4.0 (3.0, 4.9)	0.113
Patients receiving stress-dosed hydrocortisone ≥ 8 h (n, %)	9 (29.0)	5 (15.2)	0.179
Daily hydrocortisone dose (mg) (median, IQR)	150 (119, 188)	200 (129, 264)	0.202
Duration of hydrocortisone (days*) (median, IQR)	3.0 (1.9, 3.9)	2.0 (0.6, 3.8)	0.374
Laboratory Values			
Leukocyte Count, $\times 10^3/\mu\text{l}$ (median, IQR)	14.5 (13.4, 20.7)	10.8 (10.7, 14.8)	0.055
Absolute Lymphocyte Count, $\times 10^3/\mu\text{l}$ (median, IQR)	0.66 (0.54, 0.78)	1.01 (0.87, 1.54)	< 0.001
Absolute Monocyte Count, $\times 10^3/\mu\text{l}$ (median, IQR)	0.47 (0.34, 0.68)	0.78 (0.74, 1.15)	< 0.001
Lactic Acid (mg/dL) on admission (median, IQR)	3.8 (3.2, 4.9)	2.7 (2.2, 4.2)	0.112
Shock (vasopressors and lactate ≥ 2) on admission (n, %)	10 (32.3)	10 (30.3)	0.866
Short-Term Outcomes			
Proportion of Cohort developing Secondary Infections (n, %)	1 (3.2)	2 (6.1)	1.000
30-Day Mortality Rate (n, %)	3 (4.7)	6 (9.4)	0.478
Hospital Length of Stay, days (median, IQR)	10.0 (9.5, 17.4)	8.0 (8.3, 21.0)	0.472
30-Day Hospital Readmission amongst survivors ($n_{\text{alive}}/n_{30\text{-day survivors}}$, %)	4/28 (14.3)	2/25 (8.0)	0.423
Discharged status			

---Home (n, %)	13 (22.0)	15 (25.4)	0.880
---Skilled nursing facility (n, %)	13 (22.0)	11 (18.6)	0.393
---Long-term acute care hospital (n, %)	2 (3.4)	1 (1.7)	0.592
---Hospice (n, %)	0	1 (1.7)	1.000

We recruited a total of 64 critically ill patients, including 31 individuals diagnosed with sepsis and 33 non-septic control (CINS) patients. A detailed breakdown of the demographic characteristics and clinical outcomes for these patients is provided in **Table 1**. For septic patients with confirmed infections, the specific microbial sources are listed in **Appendix Table A1**. The characteristics of the CINS control group are comprehensively detailed in **Appendix Table A2**. Notably, during the 30-day follow-up period, two septic patients and two CINS patients were lost to follow-up, as illustrated in **Appendix Figure B1**.

Table 1. Patient Demographics and Clinical Outcomes.

*within 14 days following enrollment. *P*-values represent two-sample t-test comparing group means for normally distributed variables, Wilcoxon Rank Sum test comparing group medians for skewed variables, or Chi-square test comparing proportions for categorical variables.

2.2 mHLA-DR Expression Does Not Differ Between Critically Ill Patients With and Without Sepsis

While mHLA-DR expression significantly increases over the first 14 days following onset of critical illness ($p = 0.002$), this increase is driven primarily by non-septic patients ($p = 0.006$), with septic patients exhibiting only a trend towards significance over this time ($p = 0.057$, **Fig 1**). There was no significant difference between the slopes (i.e., rates of immune recovery, as assessed by mHLA-DR expression over the 14-day period) of critically ill patients with or without sepsis ($p = 0.688$).




Figure 1. Monocyte Human Leukocyte Antigen (mHLA)-DR expression over the initial 14 days following critical illness. *P*-values indicate the significance of the rate of change in mHLA-DR expression in each subgroup over time, as analyzed using a mixed-effects linear regression model.

2.3 Absolute Lymphocyte Count Does Not Differ Between Critically Ill Patients With and Without Sepsis

Absolute lymphocyte count (ALC) also significantly recovers over the 14 days following onset of critical illness ($p < 0.001$, 95% CI 0.072 - 0.259, **Fig 2**). However, in contrast to the pattern of mHLA-DR expression, this recovery is primarily driven by the septic subset of critically ill patients ($p = 0.003$, 95% CI 0.073 - 0.332), with the CINS subgroup exhibiting a trend towards significance over this period ($p = 0.059$). Although the rates of ALC recovery do not vary significantly between subgroups ($p = 0.436$), there are notable differences between the mean ALC values of each subgroup on days 1 and 7 ($p < 0.001$ and $p = 0.006$, respectively). By day 14, these differences are no longer significant ($p = 0.195$).




Figure 2. Absolute lymphocyte count (ALC) over initial 14 days following critical illness. *P*-values indicate the significance of the rate of change in ALC in each subgroup over time, as analyzed using a mixed-effects linear regression model.

2.4 Tumor Necrosis Factor Production Following Ex Vivo Endotoxin Stimulation of Whole Blood Does Not Differ Between Critically Ill Patients with and without Sepsis

LPS-stimulated cytokine production recapitulates the pattern of immune recovery modeled by mHLA-DR and ALC (**Fig 3A**). Specifically, following 18 hours of endotoxin stimulation, TNF production was observed to recover significantly over time in the combined cohort ($p < 0.001$, 95% CI 0.115 - 0.398). TNF production in septic patients increased significantly over the 14-day observation period ($p < 0.001$, 95% CI 0.195 - 0.615), although not in the CINS subset ($p = 0.253$). Rates of TNF recovery differed between subgroups ($p = 0.041$), driven primarily by differences in the concentration of this cytokine on days 1 ($p < 0.001$) and 7 ($p = 0.001$) of whole blood stimulation.




Figure 3. Ex vivo production of cytokines over time, following 18 hours of endotoxin stimulation of whole blood sampled from critically ill patients. (A) Stimulated tumor necrosis factor (TNF) production, (B) Stimulated interleukin (IL)-6 production. *P*-values indicate the significance of the rate of change in cytokine concentrations in each subgroup over time, as analyzed using a mixed-effects linear regression model.

The pattern of LPS-stimulated interleukin (IL)-6 was closely related to TNF production. In critically ill patients, IL-6 significantly increased over time ($p < 0.001$, 95% CI 0.166 – 0.513, **Fig 3B**), primarily driven by the septic subgroup ($p < 0.001$, 95% CI 0.209 – 0.726) and with CINS patients demonstrating a trend towards significant IL-6 recovery over time ($p = 0.071$). Mean IL-6 production was significantly different between each subgroup, at 1- and 7-days post-sepsis ($p = 0.002$ and 0.038), but the overall rate of IL-6 recovery (i.e., slope of the concentration of time) over the 14-day period was not significantly different between subgroups ($p = 0.147$).

2.5 Interferon-gamma Response, following Ex Vivo stimulation of Whole Blood, Varies by Stimulant Used

T lymphocyte responses play a crucial role in the adaptive immune response to sepsis. To assess these responses, we stimulated whole blood using anti-CD3 and anti-CD28 antibodies for 18 hours. While this stimulation did not result in a significant overall difference in IFN γ production from days 1 to 14 following the onset of critical illness, we did observe specific differences between mean IFN γ concentrations in each subgroup. These differences were limited to days 1 ($p = 0.048$) and 14 ($p = 0.043$) of critical illness.

Non-specific T lymphocyte stimulation, using PMA, demonstrated a more dramatic change in IFN γ production over time. Specifically, cytokine production increased substantially over 14 days of critical illness in all patients ($p < 0.001$, 95% CI 0.116 – 0.407) and in the septic subset ($p = 0.003$, 95% CI 0.12 – 0.552). The CINS subset demonstrated a less dramatic change in PMA-induced IFN γ concentrations over this time ($p = 0.059$, 95% CI -0.008–0.383). As with anti-CD3/anti-CD28 stimulation, mean IFN γ concentrations were most significant on days 1 ($p = 0.006$) and 7 ($p = 0.030$) following critical illness onset.

Since, lymphopenia is a critical component of sepsis and critical illness [31,32], we normalized interferon IFN γ production to cell count, thus distinguishing between quantitative and qualitative lymphocyte defects. When normalized to ALC, there was no statistically significant increase in stimulated IFN γ production over time. This held true whether T lymphocytes were stimulated using specific (anti-CD3/anti-CD28, Fig 4A) or non-specific (PMA, Fig 4B) agents. It also implies that, during critical illness, there is quantitative recovery of lymphocyte counts (Fig 2) although no qualitative recovery.




Figure 4. Ex vivo production of interferon (IFN) γ over time, following 18 hours of (A) anti-CD3/anti-CD28 antibody, and (B) PMA. IFN γ concentrations have been normalized to lymphocyte count. *P*-values indicate the significance of the rate of change in IFN γ concentrations in each subgroup over time, as analyzed using a mixed-effects linear regression model.

2.6 mHLA-DR Is Not Correlated with Other Measured Markers of Immunoparalysis

Using repeated measures correlation (r_{tm}), we examined the relationships among various markers of immunoparalysis. These included: (1) mHLA-DR expression, (2) ALC, (3) stimulated cytokine production, and (4) stimulated cytokine production normalized to lymphocyte count (in the case of IFN γ) and monocyte count (in the case of TNF).

Monocyte HLA-DR expression was not significantly associated with other immunoparalysis biomarkers. ALC demonstrated a weak correlation with endotoxin-stimulated TNF ($r_{tm} = 0.336$) and IL-6 ($r_{tm} = 0.351$). Additionally, ALC was weakly correlated with IFN γ concentration following anti-CD3/anti-CD28 ($r_{tm} = 0.385$) and PMA ($r_{tm} = 0.347$) stimulation.

Endotoxin-stimulated cytokines TNF and IL-6 were moderately correlated ($r_{tm} = 0.495$), with a higher correlation observed within the CINS subset ($r_{tm} = 0.576$). IFN γ concentration following T cell-specific (anti-CD3/anti-CD28) and non-specific (PMA) stimulation was also moderately correlated ($r_{tm} = 0.446$ in all patients, and 0.523 in CINS subset). When normalized to lymphocyte count, these responses to T cell stimulants remained moderately correlated ($r_{tm} = 0.359$ in all patients, and 0.529 in CINS subset).

2.7 While Biomarkers of Immunoparalysis Are Not Associated with Secondary Infection Rate, Endotoxin-Associated IL-6 Production Is Associated with 30-Day Hospital Readmission

There was no association between the concentration of each biomarker and 30-day mortality or the number of days from critical illness until death. Neither did we discover any association with 30-day secondary infection rates. In the analysis of hospital length of stay following critical illness with or without sepsis diagnosis, we found statistically significant intercepts in several quantile regression models, though these were not accompanied by associations with any of the independent variables. These findings may reflect an intrinsic difference in hospital length of stay between sepsis and CINS patients, not explained by the biomarkers used in our models.

Logistic regression revealed a statistically significant relationship between endotoxin-induced IL-6 concentration and 30-day hospital readmission ($p = 0.015$), indicating that for every unit increase in IL-6, the odds of readmission increase slightly. Additionally, there was a significant interaction between the sepsis versus CINS subgroups and hospital readmission ($p = 0.045$), with sepsis patients showing markedly higher odds of 30-day readmission compared to CINS controls (odds ratio = 27.616). While the total number of hospital readmissions was low (four readmissions among 28 septic patients who were alive at 30 days, and 2 readmissions among 25 CINS patients who were alive at 30 days), these findings may suggest that elevated endotoxin-induced IL-6 concentrations and sepsis status are important predictors of readmission.

3. Discussion

Venet et al. recently identified significant immune changes by the end of the first week post-admission for severe injury, associated with an increased risk of secondary infections, and termed 'delayed injury-acquired immunodeficiency' [25]. In a similar, though smaller, prospective observational analysis, we delved deeper into different immune surveillance markers expressed during the first two weeks of critical injury. All the biomarkers of immunoparalysis employed in the present study significantly increased over this recovery period following severe injury. When comparing sepsis and CINS subgroups, however, we noted that temporal increases in mHLA-DR were primary driven by the CINS subset of patients, while the septic subset drove increases in ALC, LPS-induced TNF and IL-6 (whether normalized to monocyte count or not), and PMA-induced IFN γ in the overall cohort. While immunoparalysis biomarkers were not associated with 30-day mortality, stimulated IL-6 production was associated with 30-day hospital readmission in the septic subset.

In a recent, retrospective analysis, Adigbli et al. reported that early, persistent lymphopenia (defined as ALC $< 1.0 \times 10^9/L$ on at least 2 days within the first 4 days of ICU admission) was associated with increased risk of death in critically ill patients with and without sepsis, with the former group demonstrating a stronger association (hazard ratios 1.89 and 1.17, respectively) [33]. Using data from patients who had ALC measured on days 1 and 7 of critical illness, we did not observe a similar association. This lack of association may be attributed to the smaller population size in our study. Mean ALC was significantly different between sepsis and CINS subgroups within the first week following enrollment, although there was no difference between groups at day 14. Surprisingly, despite lymphocytes being the predominant cellular source of IFN γ , ALC was only weakly correlated with stimulated IFN γ production over time. However, patterns of IFN γ produced in response to anti-CD3/anti-CD28 and PMA remained moderately correlated.

The cytokine response pattern to ex vivo endotoxin stimulation paralleled that of ALC. Specifically, mean TNF concentrations significantly differed between sepsis and CINS subgroups on days 1 ($p < 0.001$) and 7 ($p = 0.001$), but not on day 14. Similarly, mean IL-6 concentrations showed significant differences between subgroups on days 1 ($p = 0.0034$) and 7 ($p < 0.001$), with no significant difference on day 14 ($p = 0.147$). Specific T lymphocyte stimulation resulted in a similar pattern in IFN γ production ($p = 0.048$ on day 1 and $p = 0.043$ on day 7, with no significant difference on day 14). Non-specific T lymphocyte stimulation with PMA also reflected this pattern ($p = 0.006$ on day 1, $p = 0.030$ on day 7, and $p = 0.493$ on day 14). These findings suggest that the inflammatory response is acute and pronounced during the early stages of critical illness but tends to normalize by day 14. Comparison of immunoparalysis biomarkers between healthy volunteers and critically ill patients, over a 14-day period, may shed light on any residual deficits in immune function over the study period.

Several prior studies have described mHLA-DR as a marker of monocyte deactivation or evolving immunoparalysis, especially in the context of sepsis [34,35]. Deactivated monocytes are characterized by a loss of antigen-presenting capacity and decreased reduction of their ability to produce endotoxin-induced TNF in vitro [26,36]. De Roquetaillade et al. found that a decrease or continued low expression of mHLA-DR within the first week of ICU admission was independently linked to a higher risk of subsequent infections [37]. However, mHLA-DR has several critical shortcomings that preclude its use as a biomarker in the clinical setting, including its dependence on flow cytometry and variability in measurement and analysis [38,39]. In this respect, ALC or ex vivo assays using rapid and automated cytokine measurement platforms may offer a feasible alternative for point-of-care-testing.

In the present study, we did observe that mHLA-DR significantly recovered over time, although this increase in expression was predominant in the CINS subgroup. Considering Venet et al.'s findings [25], however, it might be more appropriate and timelier to move beyond the traditional 'sepsis' versus 'non-sepsis' classifications when studying immunoparalysis in critically ill patients.

This study had several limitations that should be acknowledged. First, due to the time-consuming nature of flow cytometry, we preserved blood samples in a protein-stabilizing solution to allow for subsequent batch processing of HLA-DR quantification. While this method is established for banking human-derived samples [40-42], the freeze-thaw process may have compromised cell integrity, potentially leading to errors in HLA-DR quantification.

Second, the study's relatively small sample size and single-center design may limit the generalizability of our findings. The small number of patients, especially in subgroup analyses, reduces the power to detect significant differences and may lead to type II errors.

Third, the study design did not allow for the assessment of the functional capacity of immune cells beyond cytokine production. Further functional assays could provide a more comprehensive understanding of the immune status of critically ill patients.

Fourth, our definition of immunoparalysis was based solely on immune parameters without considering clinical outcomes such as secondary infections. Although this approach standardizes the assessment of immunoparalysis, it may not fully capture the clinical relevance of the observed immune alterations. Despite these limitations, our findings provide valuable insights into the immune dynamics of critically ill patients with and without sepsis and highlight the need for more nuanced immune monitoring approaches.

4. Materials and Methods

4.1 Patient Cohort

Critically ill patients potentially suffering from sepsis were identified using a Modified Early Warning Scoring (MEWS) algorithm from November 2021 to March 2024. To ensure an unbiased selection process, dual, independent investigators reviewed electronically flagged patient records to identify those meeting inclusion criteria. Informed consent was obtained from patients with decision-making capacity or from legally authorized healthcare representatives for those without decision-making capacity.

Eligible participants were adults over the age of 18, within 48 hours of the onset of critical illness. Sepsis was defined according to the Sepsis-3 criteria [1]. Critical illness was defined by the need for ongoing noninvasive or invasive respiratory support and/or continuous intravenous vasopressor medications. Non-survivors were those who died within 30 days of enrollment. Patients receiving immunomodulating therapies were excluded. Measured clinical outcomes included 30-day mortality, in-hospital mortality, secondary infection rates, ICU length-of-stay and hospital readmission rates.

4.2 Cytokine Responses by Whole Blood Following Ex Vivo Stimulation

Fifty microliters of whole blood were diluted ten-fold in HEPES-buffered Roswell Park Memorial Institute (RPMI) 1640 media and exposed to specific stimulants as per established protocols [15,16]. Blood samples from each participant were treated under three conditions: (1) 500 pg/mL lipopolysaccharide (LPS) from *Salmonella enterica* strain abortus equi, (2) 500 ng/mL anti-CD3 with 2.5 µg/mL anti-CD28, or (3) 10 ng/mL phorbol 12-myristate 13-acetate (PMA) with 1 µg/mL ionomycin. After incubation for 18 hours at 37°C with 5% CO₂, concentrations of IFN γ , TNF, and IL-6 were measured in triplicate using the Ella™ automated immunoassay system (Bio-Techne, Minneapolis, MN). Data were processed using Simple Plex Runner software v.3.7.2.0 (ProteinSimple) and were available within 90 minutes.

The production of TNF was normalized to the monocyte count, and IFN γ production was normalized to the lymphocyte count, based on daily complete blood counts with automated differential profiles [16,43]. Due to the varied cellular sources of IL-6, its production was normalized to the total leukocyte count [27].

4.3 Assessment of mHLA-DR expression

One milliliter of venous blood was collected in a tube containing sodium heparin. A proteomic stabilizer (cat# 501351689, Smart Tube Inc, Las Vegas, NV) was added to the blood prior to freezing at -80°C. At the time of mHLA-DR quantification, blood was thawed per manufacturer's instructions. Quantibrite Anti-HLA-DR/Anti-Monocyte antibody

(cat# 340827 BD Biosciences, San Diego, CA) was used to stain samples for flow cytometric quantification of mHLA-DR expression. Analysis was performed using a FACS Symphony A3 (Becton Dickson & Company, Franklin Lakes, NJ) and using Flowjo v10.8.1 (BD Biosciences).

4.4 Statistical Analysis

Using SAS (v9.4; SAS Institute, Cary, NC), with a significance threshold of 0.05, we summarized variables descriptively. The distribution of continuous variables was evaluated via histograms, probability plots, and normality tests. Demographic comparisons between groups utilized Chi-square and two-sample t-tests. We employed correlation specific to repeated measures taken over time to examine the relationships among various markers of immunoparalysis.

We used a linear mixed-effects model to compare cytokine levels between septic patients and CINS controls. Due to the non-normal distribution of cytokine data, log transformation was applied before modeling. Mean cytokine concentrations were then back-transformed to their original scale, and percentage change was calculated by exponentiating the slope estimates from the model, facilitating the interpretation of cytokine dynamics. For binary outcome variables including in-hospital mortality, 30-day mortality, 30-day readmission, and secondary infections, we used a binomial logistic regression model that included factors for each cytokine on day 1 and study group. Odds ratios overall and within each study group were used to quantify the magnitude of the relationship between each biomarker and outcome variable.

5. Conclusions

This study demonstrates that immune function in critically ill patients varies significantly over the first two weeks following the onset of sepsis. Monocyte HLA-DR expression increased mainly in non-septic patients, while ALC and ex vivo cytokine production showed significant recovery in septic patients. These findings highlight the importance of nuanced immune monitoring beyond traditional sepsis classifications. Further research is needed to refine immunoparalysis markers and improve patient outcomes.

Author Contributions: Conceptualization, A.S.B.; methodology, A.S.B.; formal analysis, E.L.; investigation, A.S., A.S.B.; resources, A.S.B.; data curation, A.S.; writing—original draft preparation, A.S.B., A.S., P.B.; writing—review and editing, A.S.B., A.S., P.B., E.L.; visualization, A.S.B., E.L.; supervision, A.S.B.; project administration, A.S.B.; funding acquisition, A.S.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Institute of General Medical Sciences, grant number R35GM150695 (ASB).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Human Studies Protection Office of the Penn State College of Medicine (protocol code #15328, approved 7/30/2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: Penn State Critical Illness and Sepsis Research Center (CISRC).

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Appendix A

Table A1. Microbial sources of sepsis

Septic patient	Primary Infectious Organism (source)	Clinical diagnosis of sepsis only	Secondary Infectious Organism (source)
1	<i>Escherichia coli</i> (skin/soft tissue)		
2	<i>Staphylococcus aureus</i> (blood and sputum/respiratory)		
3	<i>Enterococcus faecalis</i> (urine), <i>Staphylococcus epidermidis</i> (blood)		
4	<i>Escherichia coli</i> (blood), <i>Klebsiella pneumoniae</i> (urine)		
5	<i>Pseudomonas aeruginosa</i> , <i>Enterococcus faecium</i> (urine)		
6	<i>Klebsiella pneumoniae</i> (blood)		

7	Beta <i>Streptococcus</i> group A (blood)	
8	Coagulase-negative <i>Staphylococcus</i> (blood), SARS-COV2 (sputum/respiratory)	
9	<i>Bacteroides Thetaiotaomicron</i> (blood)	
10	<i>Haemophilus influenza</i> , rhinovirus/enterovirus (sputum/respiratory)	Adenovirus (sputum/respiratory)
11	Influenza A, <i>Haemophilus influenzae</i> , <i>Staphylococcus aureus</i> (sputum/respiratory), <i>Staphylococcus epidermidis</i> (blood)	
12	Beta <i>Streptococcus</i> group A (blood)	
13	Beta <i>Streptococcus</i> group A (blood and skin/tissue), <i>Staphylococcus aureus</i> (tissue)	
14	<i>Staphylococcus aureus</i> (blood and skin/soft tissue)	
15	<i>Corynebacterium striatum</i> (blood)	
16	<i>Candida glabrata</i> , <i>Rhodotorula</i> sp (blood)	
17		X
18	<i>Proteus mirabilis</i> (blood and urine)	
19	<i>Candida glabrata</i> (blood and urine)	
20	<i>Escherichia coli</i> (sputum/respiratory)	
21	<i>Staphylococcus aureus</i> (blood and skin/soft tissue)	<i>Paracoccus yeii</i> (blood), <i>Enterococcus faecium</i> (skin/soft tissue)
22	<i>Proteus mirabilis</i> (blood and urine)	
23	<i>Enterobacter cloacae</i> , <i>Enterococcus faecalis</i> (abdominal)	<i>Pseudomonas aeruginosa</i> , <i>Enterococcus faecium</i> , <i>Providencia rettgeri</i> (skin/soft tissue)
24	<i>Escherichia coli</i> (blood and abdominal)	
25	<i>Morganella morganii</i> (skin/soft tissue)	
26	<i>Klebsiella oxytoca</i> (blood and urine)	
27	<i>Klebsiella pneumoniae</i> (blood and sputum/respiratory)	
28	<i>Klebsiella oxytoca</i> , <i>Enterococcus faecalis</i> , <i>Pseudomonas aeruginosa</i> (urine)	
29	<i>Staphylococcus aureus</i> (blood and urine)	
30	Respiratory syncytial virus (sputum/respiratory)	
31	Respiratory syncytial virus, SARS-COV2 (sputum/respiratory), <i>Candida</i> , <i>Lactobacillus</i> species (blood)	<i>Enterococcus faecium</i> (urine)


Table A2: Disease etiologies of patients having non-septic, critical illness

Critically ill non-septic (CINS) patient	Primary Admission Diagnosis	Primary Discharge Diagnosis
1	Cardiogenic Shock	Acute on chronic heart failure with reduced ejection fraction
2	Critical right lower extremity limb ischemia	Same
3	Type 1 dissection of ascending aorta	Same
4	Coronary artery disease	Same
5	Seizure like activity	Altered mental status, Acute respiratory failure
6	Hyponatremia and acute encephalopathy	Same
7	Heart failure with reduced ejection fraction	Hypovolemic shock
8	Hereditary angioedema	Same
9	Acute pericardial effusion	Atrial fibrillation/flutter, Pericardial effusion
10	Pulmonary embolism with acute hypoxemic respiratory failure	Same
11	Heart failure with reduced ejection fraction, status post HeartMate-3	Severe acute on chronic heart failure with LVAD, with modification of LVAD parame-

		ters
12	Acute hypoxemic respiratory failure	Same
13	Acute hypoxic respiratory failure	Same
14	Trauma secondary to motor vehicle accident	Same
15	Nonischemic cardiomyopathy with cardiogenic shock	Status post heart transplantation
16	Trauma secondary to motor vehicle accident	Same
17	Traumatic brain injury	Same
18	Acute hypoxemic respiratory failure	Jejunal fistula
19	Traumatic motorcycle accident	Sinus bradycardia
20	Convulsive status epilepticus	Same
21	Subarachnoid hemorrhage	Same
22	Acute ST elevation myocardial infarction	Same
23	Acute ST elevation myocardial infarction	Same
24	Hilar mass with pleural effusion	Acute hypoxemic respiratory failure
25	Traumatic injury	Same
26	Acute renal failure	Acute hepatic encephalopathy
27	Trauma secondary to motor vehicle accident	Same
28	Acute epiglottitis	Same
29	Hemorrhagic shock	Same
30	Fall, acute hypoxic respiratory failure	Same
31	Cardiac arrest	Same
32	Upper GI bleed	Same
33	Acute hypoxic respiratory failure, seizure disorder	Same

Appendix B

Figure B1. Flow diagram demonstrating the number of individuals included at each stage of the study.



References

1. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* **2016**, *315*, 801-810, doi:10.1001/jama.2016.0287.
2. Mikkelsen, M.E.; Still, M.; Anderson, B.J.; Bienvenu, O.J.; Brodsky, M.B.; Brummel, N.; Butcher, B.; Clay, A.S.; Felt, H.; Ferrante, L.E.; et al. Society of Critical Care Medicine's International Consensus Conference on Prediction and

- Identification of Long-Term Impairments After Critical Illness. *Crit Care Med* **2020**, *48*, 1670-1679, doi:10.1097/CCM.0000000000004586.
3. Cecconi, M.; Evans, L.; Levy, M.; Rhodes, A. Sepsis and septic shock. *Lancet* **2018**, *392*, 75-87, doi:10.1016/S0140-6736(18)30696-2.
 4. Fleischmann, C.; Scherag, A.; Adhikari, N.K.; Hartog, C.S.; Tsaganos, T.; Schlattmann, P.; Angus, D.C.; Reinhart, K.; Trialists, I.F.o.A.C. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. *Am J Respir Crit Care Med* **2016**, *193*, 259-272, doi:10.1164/rccm.201504-0781OC.
 5. Iwashyna, T.J.; Ely, E.W.; Smith, D.M.; Langa, K.M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. *JAMA* **2010**, *304*, 1787-1794, doi:10.1001/jama.2010.1553.
 6. Prescott, H.C. Preventing Chronic Critical Illness and Rehospitalization: A Focus on Sepsis. *Crit Care Clin* **2018**, *34*, 501-513, doi:10.1016/j.ccc.2018.06.002.
 7. Sun, A.; Netzer, G.; Small, D.S.; Hanish, A.; Fuchs, B.D.; Gaieski, D.F.; Mikkelsen, M.E. Association Between Index Hospitalization and Hospital Readmission in Sepsis Survivors. *Crit Care Med* **2016**, *44*, 478-487, doi:10.1097/CCM.0000000000001464.
 8. Volk, H.D.; Reinke, P.; Docke, W.D. Clinical aspects: from systemic inflammation to 'immunoparalysis'. *Chem Immunol* **2000**, *74*, 162-177, doi:10.1159/000058753.
 9. Volk, H.D.; Reinke, P.; Krausch, D.; Zuckermann, H.; Asadullah, K.; Muller, J.M.; Docke, W.D.; Kox, W.J. Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. *Intensive Care Med* **1996**, *22 Suppl 4*, S474-481, doi:10.1007/BF01743727.
 10. Hotchkiss, R.S.; Swanson, P.E.; Freeman, B.D.; Tinsley, K.W.; Cobb, J.P.; Matuschak, G.M.; Buchman, T.G.; Karl, I.E. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit Care Med* **1999**, *27*, 1230-1251, doi:10.1097/00003246-199907000-00002.
 11. Hotchkiss, R.S.; Tinsley, K.W.; Swanson, P.E.; Schmiege, R.E., Jr.; Hui, J.J.; Chang, K.C.; Osborne, D.F.; Freeman, B.D.; Cobb, J.P.; Buchman, T.G.; et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. *J Immunol* **2001**, *166*, 6952-6963, doi:10.4049/jimmunol.166.11.6952.
 12. Hotchkiss, R.S.; Schmiege, R.E., Jr.; Swanson, P.E.; Freeman, B.D.; Tinsley, K.W.; Cobb, J.P.; Karl, I.E.; Buchman, T.G. Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock. *Crit Care Med* **2000**, *28*, 3207-3217, doi:10.1097/00003246-200009000-00016.
 13. Hotchkiss, R.S.; Karl, I.E. The pathophysiology and treatment of sepsis. *N Engl J Med* **2003**, *348*, 138-150, doi:10.1056/NEJMra021333.
 14. Song, J.; Park, D.W.; Moon, S.; Cho, H.J.; Park, J.H.; Seok, H.; Choi, W.S. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. *BMC Infect Dis* **2019**, *19*, 968, doi:10.1186/s12879-019-4618-7.
 15. Bonavia, A.S.; Samuelsen, A.; Chroneos, Z.C.; Halstead, E.S. Comparison of Rapid Cytokine Immunoassays for Functional Immune Phenotyping. *Front Immunol* **2022**, *13*, 940030, doi:10.3389/fimmu.2022.940030.
 16. Bonavia, A.S.; Samuelsen, A.; Liang, M.; Hanson, J.; McKeone, D.; Chroneos, Z.C.; Halstead, E.S. Comparison of whole blood cytokine immunoassays for rapid, functional immune phenotyping in critically ill patients with sepsis. *Intensive Care Med Exp* **2023**, *11*, 70, doi:10.1186/s40635-023-00556-w.
 17. Dellinger, R.P. Inflammation and coagulation: implications for the septic patient. *Clin Infect Dis* **2003**, *36*, 1259-1265, doi:10.1086/374835.
 18. Kim, T.S.; Choi, D.H. Liver Dysfunction in Sepsis. *Korean J Gastroenterol* **2020**, *75*, 182-187, doi:10.4166/kjg.2020.75.4.182.
 19. Schwulst, S.J.; Muenzer, J.T.; Chang, K.C.; Brahmabhatt, T.S.; Coopersmith, C.M.; Hotchkiss, R.S. Lymphocyte phenotyping to distinguish septic from nonseptic critical illness. *J Am Coll Surg* **2008**, *206*, 335-342, doi:10.1016/j.jamcollsurg.2007.07.038.

20. Boomer, J.S.; Shuherk-Shaffer, J.; Hotchkiss, R.S.; Green, J.M. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. *Crit Care* **2012**, *16*, R112, doi:10.1186/cc11404.
21. Chang, K.; Svabek, C.; Vazquez-Guillamet, C.; Sato, B.; Rasche, D.; Wilson, S.; Robbins, P.; Ulbrandt, N.; Suzich, J.; Green, J.; et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. *Crit Care* **2014**, *18*, R3, doi:10.1186/cc13176.
22. Chmielewski, P.P.; Strzelec, B. Elevated leukocyte count as a harbinger of systemic inflammation, disease progression, and poor prognosis: a review. *Folia Morphol (Warsz)* **2018**, *77*, 171-178, doi:10.5603/FM.a2017.0101.
23. Parameswaran, N.; Patial, S. Tumor necrosis factor-alpha signaling in macrophages. *Crit Rev Eukaryot Gene Expr* **2010**, *20*, 87-103, doi:10.1615/critreveukargeneexpr.v20.i2.10.
24. Schrijver, I.T.; Theroude, C.; Roger, T. Myeloid-Derived Suppressor Cells in Sepsis. *Front Immunol* **2019**, *10*, 327, doi:10.3389/fimmu.2019.00327.
25. Venet, F.; Textoris, J.; Blein, S.; Rol, M.L.; Bodinier, M.; Canard, B.; Cortez, P.; Meunier, B.; Tan, L.K.; Tipple, C.; et al. Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury. *Crit Care Med* **2022**, *50*, 565-575, doi:10.1097/CCM.0000000000005270.
26. Volk, H.D.; Reinke, P.; Falck, P.; Staffa, G.; Briedigkeit, H.; Vonbaehr, R. Diagnostic-Value of an Immune Monitoring Program for the Clinical Management of Immunosuppressed Patients with Septic Complications. *Clinical Transplantation* **1989**, *3*, 246-252.
27. Samuelsen, A.M.; Halstead, E.S.; Lehman, E.B.; McKeone, D.J.; Bonavia, A.S. Predicting Organ Dysfunction in Septic and Critically Ill Patients: A Prospective Cohort Study Using Rapid Ex Vivo Immune Profiling. *Crit Care Explor* **2024**, *6*, e1106, doi:10.1097/CCE.0000000000001106.
28. Joshi, I.; Carney, W.P.; Rock, E.P. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. *Front Immunol* **2023**, *14*, 1130214, doi:10.3389/fimmu.2023.1130214.
29. Madden, G.R.; Weinstein, R.A.; Sifri, C.D. Diagnostic Stewardship for Healthcare-Associated Infections: Opportunities and Challenges to Safely Reduce Test Use. *Infect Control Hosp Epidemiol* **2018**, *39*, 214-218, doi:10.1017/ice.2017.278.
30. Gibbons, C.L.; Mangen, M.J.; Plass, D.; Havelaar, A.H.; Brooke, R.J.; Kramarz, P.; Peterson, K.L.; Stuurman, A.L.; Cassini, A.; Fevre, E.M.; et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC Public Health* **2014**, *14*, 147, doi:10.1186/1471-2458-14-147.
31. Drewry, A.M.; Samra, N.; Skrupky, L.P.; Fuller, B.M.; Compton, S.M.; Hotchkiss, R.S. Persistent lymphopenia after diagnosis of sepsis predicts mortality. *Shock* **2014**, *42*, 383-391, doi:10.1097/SHK.0000000000000234.
32. Girardot, T.; Rimmele, T.; Venet, F.; Monneret, G. Apoptosis-induced lymphopenia in sepsis and other severe injuries. *Apoptosis* **2017**, *22*, 295-305, doi:10.1007/s10495-016-1325-3.
33. Adigbli, D.; Liu, R.; Meyer, J.; Cohen, J.; Di Tanna, G.L.; Gianacas, C.; Bhattacharya, A.; Hammond, N.; Walsham, J.; Venkatesh, B.; et al. Early Persistent Lymphopenia and Risk of Death in Critically Ill Patients with and without Sepsis. *Shock* **2024**, *61*, 197-203, doi:10.1097/Shk.0000000000002284.
34. Döcke, W.D.; Randow, F.; Syrbe, U.; Krausch, D.; Asadullah, K.; Reinke, P.; Volk, H.D.; Kox, W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. *Nat Med* **1997**, *3*, 678-681.
35. Gouel-Cheron, A.; Allaouchiche, B.; Floccard, B.; Rimmele, T.; Monneret, G. Early daily mHLA-DR monitoring predicts forthcoming sepsis in severe trauma patients. *Intensive Care Med* **2015**, *41*, 2229-2230, doi:10.1007/s00134-015-4045-1.
36. Volk, H.D.; Thieme, M.; Heym, S.; Docke, W.D.; Ruppe, U.; Tausch, W.; Manger, D.; Zuckermann, S.; Golosubow, A.; Nieter, B.; et al. Alterations in function and phenotype of monocytes from patients with septic disease--predictive value and new therapeutic strategies. *Behring Inst Mitt* **1991**, 208-215.
37. de Roquetaillade, C.; Dupuis, C.; Faivre, V.; Lukaszewicz, A.C.; Brumpt, C.; Payen, D. Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections. *Ann Intensive Care* **2022**, *12*, 39, doi:10.1186/s13613-022-01010-y.

38. Peronnet, E.; Blein, S.; Venet, F.; Cerrato, E.; Fleurie, A.; Llitjos, J.F.; Kreitmann, L.; Terraz, G.; Conti, F.; Gossez, M.; et al. Immune Profiling Panel Gene Set Identifies Critically Ill Patients With Low Monocyte Human Leukocyte Antigen-DR Expression: Preliminary Results From the REAnimation Low Immune Status Marker (REALISM) Study. *Crit Care Med* **2023**, *51*, 808-816, doi:10.1097/CCM.0000000000005832.
39. Mengos, A.E.; Gastineau, D.A.; Gustafson, M.P. The CD14(+)HLA-DR^{lo}/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. *Frontiers in Immunology* **2019**, *10*, doi:ARTN 1147 10.3389/fimmu.2019.01147.
40. Rahil, Z.; Leylek, R.; Schürch, C.M.; Chen, H.; Bjornson-Hooper, Z.; Christensen, S.R.; Gherardini, P.F.; Bhate, S.S.; Spitzer, M.H.; Fragiadakis, G.K.; et al. Landscape of coordinated immune responses to H1N1 challenge in humans. *J Clin Invest* **2020**, *130*, 5800-5816, doi:10.1172/JCI137265.
41. Behbehani, G.K.; Samusik, N.; Bjornson, Z.B.; Fantl, W.J.; Medeiros, B.C.; Nolan, G.P. Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. *Cancer Discov* **2015**, *5*, 988-1003, doi:10.1158/2159-8290.CD-15-0298.
42. Nguyen, N.A.; Huang, X.; Cabrera, L.E.; Pekkarinen, P.T.; Nowlan, K.; Strandin, T.; Kantele, A.; Vapalahti, O.; Heinonen, S.; Kekäläinen, E. A comprehensive assessment of four whole blood stabilizers for flow-cytometric analysis of leukocyte populations. *Cytometry A* **2023**, *103*, 313-324, doi:10.1002/cyto.a.24700.
43. Mazer, M.B.; C, C.C.; Hanson, J.; Mannion, D.; Turnbull, I.R.; Drewry, A.; Osborne, D.; Walton, A.; Blood, T.; Moldawer, L.L.; et al. A Whole Blood Enzyme-Linked Immunospot Assay for Functional Immune Endotyping of Septic Patients. *J Immunol* **2021**, *206*, 23-36, doi:10.4049/jimmunol.2001088.